Joe Wiley

Mak­er of world's most ex­pen­sive pre­scrip­tion drug flash­es PhI­II da­ta for a po­ten­tial fourth prod­uct

Three years be­fore they be­came own­ers of the most ex­pen­sive drug in the coun­try, Am­ryt be­gan its cor­po­rate life around a sin­gle ther­a­py picked up from a small Ger­man drug­mak­er called Birken: Episal­van, an EMA-ap­proved drug for par­tial thick­ness wounds. They hoped to de­vel­op it as an or­phan drug for a con­di­tion called epi­der­mol­y­sis bul­losa, where a pa­tient’s skin be­comes as frag­ile as but­ter­fly wings. They put it al­most im­me­di­ate­ly in­to a Phase III study.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.